Addressing COVID‐19 Drug Development with Artificial Intelligence
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), the virus that led to the COVID‐19 (Coronavirus Disease 2019) pandemic, has resulted in substantial overburdening of healthcare systems as well as an economic crisis on a global scale. This has in turn resulted in widespread efforts to identify suitable therapies to address this aggressive pathogen. Therapeutic antibody and vaccine development are being actively explored, and a phase I clinical trial of mRNA‐1273 which is developed in collaboration between the National Institute of Allergy and Infectious Diseases and Moderna, Inc. is currently underway. Timelines for the broad deployment of a vaccine and antibody therapies have been estimated to be 12–18 months or longer. These are promising approaches that may lead to sustained efficacy in treating COVID‐19. However, its emergence has also led to a large number of clinical trials evaluating drug combinations composed of repurposed therapies. As study results of these combinations continue to be evaluated, there is a need to move beyond traditional drug screening and repurposing by harnessing artificial intelligence (AI) to optimize combination therapy design. This may lead to the rapid identification of regimens that mediate unexpected and markedly enhanced treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Enabling Technologies for Personalized and Precision Medicine
Ho, D., Quake, S. R., McCabe, E. R. B., Chng, W. J., Chow, E. K., Ding, X., Gelb, B. D., Ginsburg, G. S., Hassenstab, J., Ho, C.-M., et al. (2020) · Trends in Biotechnology · doi:10.1016/j.tibtech.2019.12.021 · Cited by 517
Self-citationArtificial intelligence in cancer therapy
Ho, D. (2020) · Science · doi:10.1126/science.aaz3023 · Cited by 164
Self-citation
Cited by
Applications of artificial intelligence in battling against covid-19: A literature review
Tayarani N., M.-H. (2021) · Chaos, Solitons & Fractals · doi:10.1016/j.chaos.2020.110338 · Cited by 210
Robotics and artificial intelligence in healthcare during COVID-19 pandemic: a systematic review
Sarker, S., Jamal, L., Ahmed, S. F., & Irtisam, N. (2021) · Robotics and Autonomous Systems · doi:10.1016/j.robot.2021.103902 · Cited by 199
Adly, A. S., Adly, A. S., & Adly, M. S. (2020) · Journal of Medical Internet Research · doi:10.2196/19104 · Cited by 138
Metadata
- Authors
- Ho, D.
- Venue
- Advanced Intelligent Systems
- Publisher
- Wiley
- Published
- 2020-04-27
- Volume
- 2
- Issue
- 5
- Pages
- 2000070-2000070
- ISSN
- 2640-4567 (ISSN-L)
- OpenAlex
- W3015771386
- Cited by
- 57
- References
- 2
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Addressing COVID‐19 Drug Development with Artificial Intelligence. https://app.cochat.ai/papers/10.1002/aisy.202000070
- The paper
- Ho, D. (2020). Addressing COVID‐19 Drug Development with Artificial Intelligence. Advanced Intelligent Systems. https://doi.org/10.1002/aisy.202000070
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.